This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Mary Dzhuryan is a class of 2026 PharmD candidate at the USC Alfred E. Mehrnaz Razavi Vakhshoori is a class of 2026 PharmD candidate at the USC Alfred E. The recent application was granted both priority review and orphan drug designation. Mann School of Pharmacy and Pharmaceutical Sciences in Los Angeles.
2 Guiding prescribers and patients through initiation of lumatperone, adjusting dosage amounts, and switching from other antipsychotics, emphasizing its favorable relapse reduction profile is key in preventing relapse.
Both Hadlima and Hyrimoz share the same strengths and dosages and have no clinically meaningful differences from Humira when relieving patient symptoms. The most common reason for exclusion was the patient opting out of clinical follow-up with the specialty pharmacy team.
Image Credit: Adobe Stock Images/Artur.com Key Takeaways Sanofi is shipping Beyfortus early to ensure strong supply for the 2025–2026 RSV season and avoid past shortages. As of now, supply for this coming season matches last year’s total dosage, with production expected to continue. Beyfortus cut RSV hospitalizations by up to 83.2%
It co-developed Comirnaty, the COVID-19 vaccine in partnership with Pfizer, and is gearing up for the commercial launch of its variant-adapted COVID-19 vaccine for the 2025/2026 season, pending regulatory approval. It is also developing BNT165e, an RNA-based vaccine for the prevention of P. falciparum malaria.
Construction on the new warehouse began in early 2025, and the company expects the facility to be operational in the first quarter of 2026. An expansion of the Latina site’s fill/finish line for biologics is also planned for the future.
Fixed-dose combinations contain multiple medications in a single dosage form to help simplify treatment for patients. Food and Drug Administration, Senate appropriators unanimously advanced a funding bill last Thursday that maintains agency funding in fiscal 2026 at roughly the same level as in fiscal 2025 , Politico notes.
This is apparently to support dosage adjustment in the initial three weeks without additional financial impact. However, the two drugs are not directly comparable in terms of dosage levels. Wegovy’s principal ingredient semaglutide is set to go off patent in India in March 2026, opening the door to generic semaglutide.
Preliminary results are expected in early 2026, depending on patient recruitment progress. Once safety and dosage are confirmed, the company plans to begin a phase 2a proof-of-concept study.
billion by 2026, achieving a compound annual growth rate (CAGR) of 13.2 percent CAGR between 2022 and 2026. According to recent market research , the global market for biopharmaceutical bioseparation systems, estimated to value $13 billion in 2022, is projected to grow to $19.6
The second facility for WuXi STA in the US, Phase I of the new campus will provide formulation development, clinical and commercial drug product manufacturing services for a variety of oral and injectable dosage forms, as well as packaging, labelling, storage and distribution services for clinical trial materials and commercial drug products.
AstraZeneca also claimed that CMS’s revised guidance on the Negotiation Program for Price Applicability Year 2026 (“Guidance”) interpreted the IRA in two very faulty ways, which violated the Administrative Procedure Act (APA) and harmed and will continue to harm the company. The court found numerous flaws with this argument.
Tyruko ® has the same strength/dosage form, intravenous (IV) route of administration, dosing regimen and presentation as the reference medicine, according to Sandoz. The site is planned to be completed by 2026. Tysabri ® is a registered trademark of Biogen MA, Inc.
With a career spanning over 20 years, Dr Hotha has extensive expertise in developing drug substances and products, particularly in HPAPI, Drug linkers, ADCs, and complex drug dosage forms. He has authored over 40 scientific research publications and serves on several editorial boards. internet] GlobeNewswire. Research and Markets.
Taking a step back, a Suitability Petition is used when an ANDA applicant wants to submit an ANDA that differs from its Reference Listed Drug in strength, dosage form, route of administration, or, in the case of a combination drug, active ingredient. Under 21 C.F.R.
Active Ingredient: dulaglutide Dosage Forms & Strengths: Injection: 0.75 In the US, Trulicity is protected by a compound patent (2027) and by biologics data protection (2026). mL, 3 mg/0.5 Hence, it needs to protect its patent as Trulicity patents are very vital to the company’s business as a whole.
With predictions that the global market for anticounterfeiting packaging is set to reach almost $250 billion by 2026, growth in authentication and anti-tamper devices such as holograms appear to have a healthy future.” Blister packs can also benefit from anticounterfeiting holography.
threshold by 2026. The company has classified its business into segments, including specialty pharmaceuticals, comprising radiopharmaceuticals, contract manufacturing of sterile injectables and non-sterile products, allergy therapy products, generics & APIs containing solid dosage formulations, and active pharmaceutical ingredients.
That means almost certainly no sooner than the second half of 2026. As dictated by the process provided for in the 2020 CARES Act, FDA announced issuance of the proposed order in a Federal Register notice and published the proposed order itself on FDA’s website.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content